Association of fluoropyrimidines, platinum agents, taxanes, and irinotecan in any line of chemotherapy with survival in patients with advanced gastric cancer

• Published in: Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association Vol. 14; no. 2; pp. 155 - 160
• Main Authors: Shitara, Kohei, Matsuo, Keitaro, Mizota, Ayako, Kondo, Chihiro, Nomura, Motoo, Takahari, Daisuke, Yokota, Tomoya, Ura, Takashi, Ito, Seiji, Sawaki, Akira, Tajika, Masahiro, Kawai, Hiroki, Muro, Kei
• Format: Journal Article
• Language: English
• Published: Tokyo Springer Japan 01.06.2011; Springer Nature B.V
• Subjects: Abdominal Surgery; Antineoplastic Agents - therapeutic use; Camptothecin - analogs & derivatives; Camptothecin - therapeutic use; Cancer Research; Cohort Studies; Female; Fluorouracil - therapeutic use; Gastric cancer; Gastroenterology; Humans; Kaplan-Meier Estimate; Male; Medicine; Medicine & Public Health; Middle Aged; Oncology; Original Article; Platinum Compounds - therapeutic use; Retrospective Studies; Stomach Neoplasms - drug therapy; Stomach Neoplasms - mortality; Surgical Oncology; Taxoids - therapeutic use; Platinum agent; Irinotecan; Chemotherapy; Gastric cancer; Paclitaxel; Fluorouracil

Background Although fluoropyrimidines, platinum agents, taxanes, and irinotecan are used in the treatment of advanced gastric cancer (AGC), it remains unclear whether these agents in any line of chemotherapy are associated with overall survival (OS) in these patients. Methods We retrospectively anal...